Precipio, Inc. (PRPO)
| Market Cap | 15.15M |
| Revenue (ttm) | 9.41M |
| Net Income (ttm) | -12.20M |
| Shares Out | 22.82M |
| EPS (ttm) | -0.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 48,539 |
| Open | 0.664 |
| Previous Close | 0.645 |
| Day's Range | 0.630 - 0.664 |
| 52-Week Range | 0.470 - 1.770 |
| Beta | 2.29 |
| Analysts | Buy |
| Price Target | 2.91 (+338.25%) |
| Earnings Date | May 9, 2023 |
About PRPO
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology ki... [Read more]
Financial Performance
In 2022, Precipio's revenue was $9.41 million, an increase of 6.36% compared to the previous year's $8.85 million. Losses were -$12.20 million, 43.1% more than in 2021.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for PRPO stock is "Buy." The 12-month stock price forecast is $2.91, which is an increase of 338.25% from the latest price.
News
Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call
Conference Call to be held on Monday, April 3rd, 2023 at 5:00 PM ET Conference Call to be held on Monday, April 3rd, 2023 at 5:00 PM ET
Precipio Ships First IV-Cell® Order to Major US Healthcare System
Products Division revenues begin to diversify beyond HemeScreen® Products Division revenues begin to diversify beyond HemeScreen®
CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customers
Conversion from sales funnels developed with distribution partners alongside direct sales points to continued accelerated growth Conversion from sales funnels developed with distribution partners alon...
Precipio continues to sign up and onboard HemeScreen™ customers
Conversion from sales funnels developed with distribution partners alongside direct sales points to continued accelerated growth Conversion from sales funnels developed with distribution partners alon...
ThermoFisher Salesforce Votes Precipio's HemeScreen® as “Best New Product”
HemeScreen® Technology and Product Line singled out from thousands of products distributed by Fisher Healthcare at recent National Sales Meeting HemeScreen® Technology and Product Line singled out fro...
Precipio Signs Another Major HemeScreen™ Customer
Customer's initial annual revenue expected at $650K, $2.0M revenue at full capacity Customer's initial annual revenue expected at $650K, $2.0M revenue at full capacity
Precipio Signs Additional Major HemeScreen™ Customer
Customer to begin gradually onboarding panels in Q1-2023, potential $1.2M revenue at full capacity Customer to begin gradually onboarding panels in Q1-2023, potential $1.2M revenue at full capacity
Precipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual Conference
Poster presents findings of a study of ~1000 patient samples demonstrating superior accuracy for HemeScreen™ MPN Assay Poster presents findings of a study of ~1000 patient samples demonstrating superi...
Precipio Announces Third Quarter Shareholder Update Call
Conference Call to be held on Monday, November 14th, 2022 at 5:00 PM ET Conference Call to be held on Monday, November 14th, 2022 at 5:00 PM ET
Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™
Adding customer segment exceeding $100M in market potential Adding customer segment exceeding $100M in market potential
Sharon Robins Joins Precipio's Products Division as Senior Director of Laboratory & Hospital Sales
Precipio continues to build strong team in anticipation of substantial growth in the next 12 months Precipio continues to build strong team in anticipation of substantial growth in the next 12 months
Precipio Launches New 1-Step Technology for all HemeScreen Assays
New technology enables same day test results by eliminating extra confirmation step New technology enables same day test results by eliminating extra confirmation step
Toni-Ann Mills Joins Precipio's Products Division to Lead Channel Partner Training, Learning & Development
Precipio prepares to launch a nationwide HemeScreen sales effort of 250+ sales reps from AmerisourceBergen, ThermoFisher, and other distributors Precipio prepares to launch a nationwide HemeScreen sal...
Precipio Announces Second Quarter Shareholder Update Call
Conference Call to be held on Monday, August 15th, 2022 at 5:00 PM EST Conference Call to be held on Monday, August 15th, 2022 at 5:00 PM EST
Precipio to distribute HemeScreen® through Fisher Healthcare channel
Agreement Enhances Precipio's Product Reach to US Laboratories Agreement Enhances Precipio's Product Reach to US Laboratories
Precipio requests that all Stockholders that have not yet voted, proceed to cast their vote
Meeting Adjourned, new meeting set for July 5th at 10am EDT Meeting Adjourned, new meeting set for July 5th at 10am EDT
Keith Meadors Joins Precipio to Lead its Products Division
Seasoned, experienced industry executive with a track record of managing 9-figure revenue sales organizations Seasoned, experienced industry executive with a track record of managing 9-figure revenue ...
Precipio Receives CE-IVD Certification to Market Multiple HemeScreen® Panels in Europe
This Regulatory Approval Opens the Company's Reach to the European Market This Regulatory Approval Opens the Company's Reach to the European Market
Precipio Signs First IV-Cell Customer Agreement
Laboratory operating both HemeScreen® & IV-Cell® demonstrates significant cross-sell potential Laboratory operating both HemeScreen® & IV-Cell® demonstrates significant cross-sell potential
Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , is excited to announce its participation and the presentation of HemeScreen...
Precipio Announces 2021 Fourth Quarter and Year-End Shareholder Update Call
Conference Call to be held on Monday, April 4th, 2022 at 5:00 PM EST Conference Call to be held on Monday, April 4th, 2022 at 5:00 PM EST
Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO
NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced that Mr. Carl Iberger, Precipio's CFO for the past five years,...
Precipio Releases Year-End 2021 Preliminary Unaudited Results and Outlook for 2022
NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced its unaudited and preliminary results for 2021. The Company ant...
New York State Approves Precipio's HemeScreen for POL clinical use
New York Cancer & Blood POL will commence the use of HemeScreen in its laboratory New York Cancer & Blood POL will commence the use of HemeScreen in its laboratory
Precipio Announces Q3-2021 and year-end Shareholder Update Call
Conference Call to be held on Monday, November 15th, 2021 at 5:00 PM EST Conference Call to be held on Monday, November 15th, 2021 at 5:00 PM EST